Radiopharm Partners with Siemens Healthineers for RAD101 Phase 3 Clinical Supply
RADX sits 24% above its 52-week low of $3.496 on light trading volume (0.3× avg).
Summary
Radiopharm Theranostics has signed a clinical supply agreement with Siemens Healthineers for RAD101, ensuring manufacturing and distribution for its upcoming Phase 3 trial in the U.S. for brain metastases.
Key Events · Product Development and Regulatory · RADX
-
Clinical Supply Agreement Signed
Radiopharm Theranostics has partnered with Siemens Healthineers for the radiolabeling and distribution of RAD101 (Fluorine-18 labeled) in the U.S.
-
Ensures Phase 3 Trial Supply
The agreement secures sufficient supply of RAD101 for the initiation of the multi-center global Phase 3 registrational trial in the U.S., following topline data readout from the Phase 2b trial in H1 2026.
-
Positive Phase 2b Interim Data
Interim analysis from the Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance with MRI (primary endpoint).
-
FDA Fast Track Designation
RAD101 has previously received U.S. Food and Drug Administration (FDA) Fast Track Designation for distinguishing recurrent disease from treatment effects in brain metastases.
Analysis · RADX · Life Sciences
This agreement with Siemens Healthineers is a critical step for Radiopharm Theranostics, securing the manufacturing and distribution of RAD101 for its upcoming multi-center global Phase 3 registrational trial in the U.S. For a clinical-stage company, ensuring a reliable supply chain for a pivotal trial significantly de-risks the development pathway. The positive interim Phase 2b data, showing 90% concordance with MRI in brain metastases, combined with FDA Fast Track Designation, underscores the potential of RAD101. This partnership provides essential operational support as the company advances a key pipeline asset towards potential commercialization.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 962 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $4.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.5M. The 52-week trading range was $3.50 to $16.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.